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Abstract
Background: The risk of several types of cancer is increased in type 2 diabetes mellitus. The earliest possible
diagnosis of cancer – difficult within regular outpatient diabetes care - is of utmost importance for patients’ survival.
The aim of this multicenter, retrospective (years 1998–2015), case-control study was to identify risk factors
associated with malignancy in subjects with diabetes treated in a typical outpatient setting.
Methods: In the databases of 3 diabetic and 1 primary care clinics 203 patients (115 women) with type 2 diabetes
mellitus who developed malignancy while treated for diabetes were identified. The control group consisted of 203
strictly age- and gender matched subjects with type 2 diabetes without cancer. Factors associated with diabetes:
disease duration, antidiabetic medications use and metabolic control of diabetes were analyzed. Also other
variables: BMI (body mass index), smoking habits, place of residence and comorbidities were included into analysis.
Results: The most prevalent malignancies in men and women together were breast cancer (20.7 %) and colorectal
cancer (16.3 %). HbA1c (hemoglobin A1c) level ≥8.5 %, obesity and insulin treatment in dose-dependent and time-
varying manner demonstrated significant association with increased risk of malignancy, while metformin use was
associated with a lower risk of cancer. Diabetes duration, comorbidities, smoking habits, place of residence and
aspirin use did not show significant association with risk of malignancy.
Conclusions: In the outpatient setting the obese patients with poorly controlled insulin treated type 2 diabetes
mellitus should be rigorously assessed towards malignancies, particularly breast cancer in women and colorectal
cancer in men.
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Background
Association between diabetes and cancer has been
known for decades [1, 2]. Type 2 diabetes mellitus
(T2DM) can be considered as a risk factor of several
types of malignant neoplasms [3–11]. In cancer develop-
ment both genetic and environmental factors play an
important role [12, 13]. Among possible biological
mechanisms directly linking diabetes and cancer,
hyperinsulinemia, hyperglycemia and inflammation are
pointed out [14–16].
It is widely assumed that glucose-lowering therapy
may influence malignancy risk in diabetic subjects. Met-
formin is considered to play a protective role in cancer
development and outcomes [17], whilst exogenous insu-
lin use seems to be associated with an elevated cancer
risk [18]. Oncogenic effects of newer antidiabetic medi-
cations is still a matter of uncertainty [19]. Since the
earliest possible diagnosis of cancer is of utmost import-
ance for patients’ survival, identification of clinically rele-
vant risk factors of cancer among diabetic patients may
be helpful in identifying subjects at greater risk of
malignancy.
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The aim of this multicenter, retrospective, case-control
study was to identify risk factors associated with malig-
nancy in subjects with diabetes treated in a typical out-
patient setting.
Methods
The study was approved by the institutional Bioethics
Committee at the University of Rzeszow and by the all
appropriate administrative bodies. The study was carried
out in accordance with ethical standards laid down in
Polish regulations and in an appropriate version of the
Declaration of Helsinki (as revised in Brazil 2013).
After Bioethics Committee approval, we performed
retrospective analysis of existing individual patients’ re-
cords in the databases of 3 diabetic and 1 primary care
clinics. Inclusion criteria for the ‘case’ group included:
cancer diagnosed after diagnosis of type 2 diabetes, at
least one HbA1c measurement before or at the time of
cancer diagnosis, date of diabetes diagnosis, diabetes
treatment, BMI and history of comorbidities available.
We identified 203 patients (115 women) with T2DM eli-
gible for analysis. Data analysis covered the period from
January 1998 (the first eligible patient with diagnosed
cancer) to 30 April 2015. The mean age of diabetic pa-
tients at the time of cancer diagnosis was 67.1 ± 9.7 years,
and 141 persons were aged ≥65 years. The control group
consisted of 203 strictly age- and gender matched sub-
jects with T2DM without cancer. Patients were selected
from the same databases in the case-control manner,
with the 1:1 ratio. For each ‘case’ patient, an eligible
‘control’ subject with the same gender, and with the
nearest possible date of birth was chosen, and any given
pair was recruited always at one center to avoid impact
of different treatment algorithms used in different
clinics. Individuals who died within the analyzed time
period but before the moment of data collection were
also included into the analysis if their data were avail-
able. Data for patients with malignancy were taken from
the period preceding cancer diagnosis (index time). Data
for the ‘control’ subjects were assessed from the same
index time, i.e., if the ‘case’ patient had cancer diagnosed
in April 2009, the data for his/her comparator were
taken from the same period.
In both groups metabolic control of diabetes (mean
HbA1c from the preceding up to 3 years before index
time, if available), diabetes duration, antidiabetic medica-
tions (also from the preceding up to 3 years, and each
drug was classified as “used” if it was taken for at least
6 months), mean insulin dose from the preceding
6 months, and duration of insulin treatment up to the
moment of cancer diagnosis were analyzed. Also place
of residence (rural, small cities or urban), smoking habits
(current, former or never smoker), presence of comor-
bidities (hypertension, hyperlipidemia and cardiovascular
disease), BMI and use of aspirin were also included into
the analysis. All included patients were of Caucasian eth-
nicity. Detailed characteristics of both groups is pre-
sented in the Table 1.
Current place of residence was taken into analysis with
the exception of patients, who moved in the last year. In
such cases a previous place of residence was taken into
account. Patients were considered as a current, former
or never smokers according to definition stated by
Centers for Disease Control and Prevention [20]. Hyper-
tension was considered if blood pressure values were
≥140 mmHg for systolic, and/or ≥90 mmHg for diastolic
blood pressure, or if antihypertensive medications were
used. Hyperlipidemia was recognized if LDL-cholesterol
level was ≥2.6 mmol/L (100 mg/dl) and/or triglycerides
concentration was ≥1.7 mmol/L (150 mg/dl), or hypoli-
pemic drugs were used. Cardiovascular disease was con-
firmed if the patient had a history of non-fatal
myocardial infarction, hospitalization for acute coronary
syndrome, non-fatal stroke, revascularization or
amputation.
Statistical analysis of the data was performed using
SigmaPlot for Windows version 12.5 (Systat Software
Inc., San Jose, CA, USA). The analysis was performed in
2 stages. In the first stage comparison of the two groups
was made. The continuous data were analyzed using an
unpaired two-tailed Student’s t-test or by a Mann-
Whitney rank sum test where appropriate. The categor-
ical data were compared using χ2 test. In the second
stage patients were divided into subgroups according to
BMI (<25.0, 25.0–29.9, 30.0–34.9 and ≥35.0 kg/m2), dia-
betes duration (<5.0, 5.0–9.9, 10.0–14.9 and ≥15.0 years),
insulin dose (no insulin, <0.50 and ≥0.50 IU/kg) and
duration of insulin treatment (no insulin, <5.0, 5.0–9.9
and ≥10.0 years). For the assessment of the effect of
treatment or analyzed risk factors on cancer occurrence
OR (odds ratios) and 95 % CI (confidence intervals) were
calculated in univariate and in multiple logistic regres-
sion models. A P value <0.05 was considered statistically
significant.
Results
The most prevalent malignancies in the whole group
were: breast, colorectal and uterine cancers (Fig. 1).
Among women the most prevalent cancer sites were:
breast (36.5 %), uterus (13.9 %), colon with rectum
(9.6 %), lung (5.2 %) and stomach (4,4 %), while in men
there were: colon with rectum (25.0 %), prostate
(13.6 %), kidney (10.2 %), lung (10.2 %) and pancreas
(9.1 %).
Metabolic control
Mean HbA1c level was not significantly different be-
tween the case and control groups. However, a sharp
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increase of cancer risk was observed among patients
with HbA1c level ≥8.5 % (Fig. 2), and these patients had
significantly elevated risk of malignancy compared with
the remaining subjects, OR 1.802 (1.030–3.153), p =
0.037.
Diabetes duration
Duration of diabetes did not differ significantly between
the two groups. Also when patients were divided into
four groups according to diabetes duration, no signifi-
cant differences were found (Fig. 2).
Diabetes treatment
Significantly fewer patients in the case group were
treated with metformin compared to the control group
(Table 1). This difference was significant both in the uni-
variate analysis and after adjustment for BMI, diabetes
duration, metabolic control, other antidiabetic medica-
tions use and all other variables. Insulin use both in the
crude analysis and after adjustment for BMI, diabetes
duration and metabolic control was associated with sig-
nificantly elevated risk of cancer occurrence. After ad-
justment for other variables in the multiple logistic
regression analysis it was attenuated to non-significant
Table 1 Characteristics of the case and control groups
Parameter Malignancy No malignancy P value*
Age at index time (years) (mean ± SD) 67.1 ± 9.7 67.1 ± 9.7 -
< 65 years (n) 62 (30.5 %) 62 (30.5 %)
≥ 65 years (n) 141 (69.5 %) 141 (69.5 %)
Gender -
male (n) 88 (43.3 %) 88 (43.3 %)
female (n) 115 (56.7 %) 115 (56.7 %)
Place of residence 0.264
rural (n) 38 (18.7 %) 44 (21.7 %)
cities <50,000 inhabitants (n) 27 (13.3 %) 36 (17.7 %)
cities >50,000 inhabitants (n) 138 (68.0 %) 123 (60.6 %)
Smoking habits 0.838
never smokers (n) 115 (56.7 %) 117 (57.6 %)
former smokers (n) 54 (26.6 %) 57 (28.1 %)
current smokers (n) 33 (16.3 %) 29 (14.3 %)
unknown status (n) 1 (0.5 %) -
BMI (kg/m2) (mean ± SD) 30.8 ± 5.3 30.1 ± 4.7 0.103
Comorbidities
cardiovascular disease (n) 50 (24.6 %) 58 (28.6 %) 0.369
hypertension (n) 177 (87.2 %) 179 (88.2 %) 0.763
hyperlipidemia (n) 153 (75.4 %) 159 (78.3 %) 0.480
Diabetes duration (years) (mean ± SD) 10.7 ± 7.4 10.3 ± 8.1 0.262
HbA1c (%) (mean ± SD) 7.39 ± 1.21 % 7.30 ± 1.06 % 0.755
Antidiabetic medications
metformin (n) 126 (62.1 %) 167 (82.3 %) <0.001
sulfonylurea (n) 83 (40.9 %) 101 (49.8 %) 0.090
acarbose (n) 18 (8.9 %) 14 (6.9 %) 0.581
DPP-4 inhibitor (n) 11 (5.4 %) 6 (3.0 %) 0.322
insulin (n) 110 (54.2 %) 81 (39.9 %) 0.005
insulin dose (IU/kg/24 h) (mean ± SD) 0.59 ± 0.31 0.53 ± 0.24 0.407
insulin duration (years) (mean ± SD) 6.2 ± 5.6 6.5 ± 4.9 0.529
Aspirin use (n) 102 (52.6 %) 102 (52.8 %) 0.957
unknown status 9 10
NS non significant
* between malignancy and non-malignancy groups
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level. No significant associations were found for other anti-
diabetic medications, with the exception of DPP-4 (dipepti-
dyl-peptidase −4) inhibitors, which after adjustment to all
analyzed covariates appeared to be associated with elevated
risk of cancer occurrence (Fig. 2 and Table 2). However,
only 17 patients (4.2 %) among the whole group of 406 sub-
jects were treated with these medications.
Although mean insulin dose and mean duration of in-
sulin use were not significantly different between the
case and control groups, insulin treatment has shown
association with the risk of malignancy occurrence in a
dose-dependent and time-varying manner (Ptrend 0.015
and 0.027 respectively). The risk of cancer was increas-
ing together with increasing insulin dose and the highest
Fig. 1 Cancer sites with over 4 % prevalence in the studied population
Fig. 2 Diabetes-related risk factors of cancer occurrence
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risk was revealed in patients using insulin at a dose
≥0.50 IU/kg. Interestingly, the highest risk was observed
in the first 10 years of insulin therapy and it was
decreasing thereafter (Fig. 2).
BMI
Mean BMI was not significantly different between the
case and control groups. However, risk of malignancy
was increasing with the increasing BMI (Fig. 3).
Obesity (BMI ≥30 kg/m2) was associated with signifi-
cantly elevated risk of malignancy, OR 1.608 (95 % CI
1.087–2.380), P = 0.022 compared to patients with
lower BMI. After adjustment for duration of diabetes,
its metabolic control and antidiabetic medications use
this relationship become even stronger, OR 2.013
(1.310–3.092), P = 0.001.
Other variables
None of the other analyzed variables had significant
effect on risk of malignancy among study participants
(Fig. 3). Only among patients with lung cancer smoking
(ever vs. never) was associated with significantly elevated
risk of malignancy, OR 11.000 (1.998–60.572), P = 0.003.
No association was found for other site-specific cancers.
Discussion
Although the link between diabetes and malignant neo-
plasms is well known and many site-specific cancers are











































a adjusted for BMI, diabetes duration and metabolic control
b adjusted for BMI, diabetes duration, metabolic control and antidiabetic medications use
c adjusted for BMI, diabetes duration, metabolic control, antidiabetic medications use, smoking history, place of residence, presence of comorbidities and
aspirin use
Data presented in bold are statistically significant
Fig. 3 Anthropometric and demographic-related risk factors of cancer occurrence
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more prevalent in diabetic patients [3–11], the exact risk
factors of cancer in diabetic population have not been
fully determined. Also in our study prevalence of breast,
colorectal, uterine, kidney, pancreatic and gastric cancers
among diabetic patients was higher, while proportion of
patients with prostatic and lung cancers was lower than
observed in the general Polish population [21], which is
in line with majority of other observations [4–7, 22].
Our retrospective, multicenter, case-control study re-
vealed that the following diabetes-related factors may be
associated with cancer occurrence: poor metabolic con-
trol, obesity and antidiabetic medications use. Import-
antly, age and gender were not included into risk
analysis, because the patients were strictly matched ac-
cording to them.
Data regarding association between HbA1c level and risk
of malignancy are divergent. Some studies showed con-
tinuous relationship between increasing HbA1c level and
cancer risk [23–25], others found non-linear association
[26, 27] (the second one only among women), or elevated
risk of malignancy above the specified HbA1c threshold of
7.5 % (colorectal cancer) [28]. In the study by Miao
Jonasson et al. no relationship between HbA1c level and
cancer was found [29]. In the recent meta-analysis signifi-
cant association between chronic hyperglycemia and ele-
vated risk of several types of malignancies with the
exception of prostate cancer was demonstrated [30]. We
took to the analysis the mean HbA1c level from a longer
period of time preceding cancer diagnosis considering it
as better reflecting the overall exposure to glucose than
single measurement. In our study risk of malignancy was
rising rapidly at the HbA1c level equal or above 8.5 %. de
Beer and Liebenberg found similar HbA1c threshold for
the risk of colorectal and breast cancers [30]. In our study
these cancers were 37 % of all malignancies, which partly
explains our findings.
Some of the studies cited above were performed in dia-
betic populations [23–25, 29], while other were conducted
in both non-diabetic and diabetic subjects [26–28]. Al-
though deleterious effect of glucose and elevated cancer
risk as a function of HbA1c may be seen also in a higher
versus lower values within a normal range, it can be more
pronounced at high glucose concentrations. The higher
threshold found in our study can be explained by the fact
that prolonged hyperglycemia leads to formation of ROS
(reactive oxygen species) and to accumulation of AGEs
(advanced glycation end products). AGEs stimulate their
specific receptor RAGE (receptor for AGE) which leads to
increased inflammation through the activation of the nu-
clear transcription factor NF-κB and formation of ROS in
the cells, which have mutagenic effect and cause DNA
damage. This pathway is considered to play an important
role in both inflammation and carcinogenesis [31, 32].
Chronic hyperglycemia activates these biological processes
and thus a higher HbA1c value may reflect higher cancer
risk in poorly controlled diabetes. In addition, glucose
serves is a primary energy source for cancer cells, and
higher glucose concentrations may accelerate cancer
growth [33, 34].
Data regarding effect of diabetes duration on cancer
risk are scarce. Johnson et al. and the Danish registry
study documented highest cancer risk occurring imme-
diately after diabetes diagnosis [35, 36]. However, Li et
al. demonstrated opposite results, with the lowest risk of
malignancy in the first 5 years from the onset of dia-
betes, and the highest cancer risk among patients with
diabetes lasting over 15 years [37]. In our study there
was a clear tendency towards lowest cancer risk in the
first years, and the highest risk between 10 and 15 years
after diagnosis of diabetes. The increasing risk of cancer
incidence with duration of diabetes can be explained by
cumulative effect of hyperglycemia, use of insulin, and
weight gain developing in the course of the disease. In
addition, increasing age itself is strongly associated with
increasing cancer risk both in diabetic and non-diabetic
population [21, 38].
Impact of antidiabetic medications on cancer risk has
been widely discussed in recent years. As a progressive
disease type 2 diabetes requires intensification of treat-
ment over time, from lifestyle modification through oral
therapy in different regimens, to insulin treatment. Thus,
a clear impact of antidiabetic medications on cancer risk
is difficult to determine.
Our study demonstrated highly significant reduction
of cancer risk among metformin users, which is in line
with many [17, 19, 39, 40] but not all [41] studies. The
mechanisms of the anti-cancer effect of metformin in-
clude inhibition of cancer cells growth through stimula-
tion of AMPK (AMP-activated protein kinase) and its
regulator LKB1 (liver kinase B1), which is known to act
as a tumor suppressor protein. In addition, metformin
also directly inhibits mTOR (mammalian target of rapa-
mycin) pathway [42] and may have a role of immuno-
modulator [43].
Sulfonylurea (SU) use in our study did not show rela-
tionship with cancer risk. Data from other observations
are divergent. Soranna et al. demonstrated neutral effect
of SU derivates on the risk of malignancy [39]. This was
confirmed by Monami et al. with the exception of glicla-
zide, which appeared to be protective [44]. On the other
hand, recently Thakkar et al. revealed increased cancer
risk among SU users [40].
Current evidence from observational studies indicate
harmful effect of insulin on the cancer risk [18, 37]. In
our study insulin use was associated with a dose-
dependent elevated risk of malignancy. Similar relation-
ship was also observed by Holden et al. [45]. Regarding
duration of insulin treatment, risk of malignancy in our
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observation was highest in the first 10 years of treat-
ment, and become insignificant with a longer insulin
use. This phenomenon can be explained by increased
cancer and also coronary heart disease mortality ob-
served among diabetic patients treated with insulin [46].
Other studies showed increased risk of malignancy asso-
ciated with insulin use after 4 years of insulin treatment
[18]. In general, insulin is a potent growth stimulating
hormone acting through insulin and IGF-1 (insulin-like
growth factor-1) receptors [34, 47, 48]. On the other
hand, landmark prospective studies in type 2 diabetes
did not confirm elevated risk of malignancy associated
with more intensified treatment [49]. Also Outcome Re-
duction with an Initial Glargine Intervention (ORIGIN)
trial did not demonstrated raised cancer risk among in-
sulin users [50]. However, these studies were of limited
duration, also relatively low doses of insulin were used
in the ORIGIN trial.
The number of patients treated with other antidiabetic
medications in our study was small, therefore we were
unable to determine their relationship with cancer risk.
Acarbose (the α-glucosidase inhibitor) is not popular
due to its well-known side effects. DPP-4 inhibitors are
not reimbursed in Poland and their utilization is low. In
our study, after adjustment to all analyzed variables they
demonstrated significant association with cancer risk.
However, it is worth to notice that only 17 patients were
treated with these agents and in this case random effect
cannot be excluded. Pioglitazone and SGLT-2 inhibitors
are also not reimbursed and, in addition, pioglitazone
was not available on market in Poland up to 2014, thus
number of patients using these medications is extremely
low.
Obesity is a well-recognized risk factor of several types
of cancer [51, 52]. Our study confirmed association be-
tween obesity and risk of malignancy in diabetic popula-
tion. Obese patients, especially with severe obesity (BMI
≥35 kg/m2), had significantly higher risk of cancer oc-
currence compared with non-obese subjects. It should
be remembered that with cancer development body
weight frequently decreases, the fact which may mar
analysis of the results. Insulin resistance, hyperinsuline-
mia, elevated levels of IGF-1, inflammation, increased
sex hormones bioavailability and hyperglycemia are con-
sidered to be responsible for increased cancer risk in
obese individuals [53].
Smoking is known to be associated with elevated risk of
several site-specific cancers, especially lung cancer [54].
Interestingly, in our study number of never, former and
current smokers was not significantly different in case and
control groups, and smoking was not associated with ele-
vated overall cancer risk. However, not surprisingly, num-
ber of current and former smokers was significantly higher
in patients with lung cancer related to their comparators.
For other analyzed variables, including place of resi-
dence, presence of comorbidities and aspirin use rela-
tionship with risk of malignancy was not revealed.
The limitations of our study include its retrospective
and observational design, and relatively small sample
size which has influenced the statistical power of our
findings, and has not allowed to demonstrate other pos-
sible relationships for which positive trends were ob-
served. Also immortal time, time-window and time-lag
biases despite our best efforts cannot be excluded [55].
Another limitation is low number of users of oral drugs
other than sulfonylurea derivatives and metformin. In
addition, all main cancer risk factors confirmed in the
study e.g., insulin use, HbA1c level and obesity heavily
influence one another which may also confound the re-
sults. And finally, due to the characteristics of Polish so-
ciety, only patients of Caucasian ethnicity were included
and our findings may have not be applicable for persons
from other ethnic groups.
This study has also several strengths. One of them is
its case–control design with strictly matched pairs of
case subjects and their comparators, with each pair
taken from the very same center. The study was based
on a high-quality data sources using samples with a long
follow-up time (mean time from diabetes diagnosis to
index time has exceeded 10 years) and extensive covari-
ate information, including the date of the onset of dia-
betes, date of cancer diagnosis, treatment details,
metabolic control and other common risk factors, which
allowed to explore the relationship between T2DM and
cancer risk.
Conclusions
The elderly obese patients with long-standing and poorly
controlled type 2 diabetes treated with high doses of insu-
lin are at high risk of cancer development and they should
be rigorously assessed towards malignancies, particularly
breast cancer in women and colorectal cancer in men.
The results of our study indicate also that metformin
therapy should be implemented in all patients without
contraindications and without intolerance to this drug. In-
sulin in type 2 diabetic patients should be introduced with
caution and, if possible, high doses of insulin should be
avoided. In addition, strong oncological vigilance should
be maintained during the first 10 years of insulin treat-
ment. On the other hand, also deterioration of metabolic
control should be avoided and increase of HbA1c level
above the threshold of 8.5 % should not be allowed.
Finally, our study indicated the important role of
weight management in patients with type 2 diabetes.
Thus, it is strongly reasonable to strive for weight reduc-
tion in obese diabetic patients to reduce risk of obesity-
related complications, including malignancy.
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